Indication
Haemophilus influenzae type b vaccination
Haemophilus influenzae type b vaccination is an active immunization procedure indicated for the prevention of invasive disease caused by the encapsulated bacterium *Haemophilus influenzae* serotype b. Read more about Haemophilus influenzae type b vaccination
15 drugs 5 manufacturers
Drugs that treat it
Common Haemophilus influenzae type b vaccination therapies.
PEDVAX HIB (PF) (Haemophilus b conjugate vaccine (meningococcal prot.conj)/PF)
PENTACEL ACTHIB COMPONENT (PF) (Haemophilus B polysacc conj-tetanus tox,component 2 of 2/PF)
VAXELIS (diphtheria,pertus(acell),tetanus/hepB/polio/Hib conj-meng/PF)
VAXELIS (diphtheria,pertus(acell),tetanus/hepB/polio/Hib conj-meng/PF)
PENTACEL (diphtheria,pertussis(acell),tetanus,polio/Haemophilus B/PF)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonHaemophilus influenzae type b vaccination is an active immunization procedure indicated for the prevention of invasive disease caused by the encapsulated bacterium *Haemophilus influenzae* serotype b.
The target organism primarily threatens infants and children younger than five years of age, as well as individuals with anatomic or functional asplenia and other immunocompromising conditions.
In unimmunized populations, the pathogen colonizes the nasopharynx and can breach mucosal barriers to enter the bloodstream, resulting in severe, life-threatening systemic manifestations including purulent meningitis, epiglottitis, bacteremic pneumonia, septic arthritis, and fulminant septicemia.
- fda.gov
Haemophilus influenzae type b vaccination is an active immunization procedure indicated for the prevention of invasive disease caused by the encapsulated bacterium *Haemophilus influenzae* serotype b
- fda.gov
Haemophilus influenzae type b vaccination is an active immunization procedure indicated for the prevention of invasive disease caused by the encapsulated bacterium *Haemophilus influenzae* serotype b
- cdc.gov
The target organism primarily threatens infants and children younger than five years of age, as well as individuals with anatomic or functional asplenia and other immunocompromising conditions In unimmunized populations, the pathogen colonizes the nasopharynx and can breach mucosal barriers to enter the bloodstream, resulting in severe, life-threatening systemic manifestations including purulent meningitis, epiglottitis, bacteremic pneumonia, septic arthritis, and fulminant septicemia
- cdc.gov
The target organism primarily threatens infants and children younger than five years of age, as well as individuals with anatomic or functional asplenia and other immunocompromising conditions
- nih.gov
The target organism primarily threatens infants and children younger than five years of age, as well as individuals with anatomic or functional asplenia and other immunocompromising conditions
- vaccinesafety.edu
In unimmunized populations, the pathogen colonizes the nasopharynx and can breach mucosal barriers to enter the bloodstream, resulting in severe, life-threatening systemic manifestations including purulent meningitis, epiglottitis, bacteremic pneumonia, septic arthritis, and fulminant septicemia
- cdc.gov
In unimmunized populations, the pathogen colonizes the nasopharynx and can breach mucosal barriers to enter the bloodstream, resulting in severe, life-threatening systemic manifestations including purulent meningitis, epiglottitis, bacteremic pneumonia, septic arthritis, and fulminant septicemia
Personalize your experience
Follow Haemophilus influenzae type b vaccination and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.